Mylan Launches MPA Injectable Suspension for Prevention of Pregnancy in the US
- Generic launch of Pfizer's Depo-Provera- Medroxyprogesterone Acetate (MPV) IV 150mg- is a Single-Dose Vial- which is in response to the FDA’s ANDA approval for the drug
- The launch will support the birth control rate in the US- with safety concerns of not using it more than 2 years as can lead to lose of bone mineral density
- According to IQVIA- Mylan has 179 ANDAs having pending FDA approval with ~$89.3B annual brand sales and in 31 July- 2018 MPA’s sales in the US was ~$181M
Ref: Mylan | Image: WVNews
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].